Derynck Mika K's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Aug 6, 2026
- Accession no.
- 0001865125-26-000004
- Filed
- Aug 6, 2026, 8:18 PM ET
- Trade date
- Aug 4, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $9.56M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Derynck Mika KCIK 0001865125 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Common Stock | MOption exerciseAcquired | +87,373 | $2.48 | +$216,685.04 | 87,373 | Direct | |
| Aug 4, 2026 | Common Stock | MOption exerciseAcquired | +27,567 | $25.28 | +$696,893.76 | 114,940 | Direct | |
| Aug 4, 2026 | Common Stock | MOption exerciseAcquired | +23,364 | $14.85 | +$346,955.4 | 138,304 | Direct | |
| Aug 4, 2026 | Common Stock | MOption exerciseAcquired | +20,491 | $22.47 | +$460,432.77 | 158,795 | Direct | |
| Aug 4, 2026 | Common Stock | SSaleDisposed | −158,795 | $60.21F2 | −$9,561,586.85 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Common Stock | MOption exerciseDisposed | −87,373 | $0.00 | $0 | 0 | Direct | |
| Aug 4, 2026 | Common Stock | MOption exerciseDisposed | −27,567 | $0.00 | $0 | 0 | Direct | |
| Aug 4, 2026 | Common Stock | MOption exerciseDisposed | −23,364 | $0.00 | $0 | 0 | Direct | |
| Aug 4, 2026 | Common Stock | MOption exerciseDisposed | −20,491 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.